Hemolytic uremic syndrome following Campath-1H induction.
Hemolytic uremic syndrome (HUS) is a rare complication following solid organ transplantation. We report on a patient who underwent renal transplantation using Campath-1H induction and tacrolimus maintenance therapy who developed HUS, which was managed by plasma exchange and switch to Rapamycin. However, graft function could not be restored.
Bonatti
Hugo
H
Department of General and Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Brandacher
Gerald
G
Boesmueller
Claudia
C
Cont
Micol
M
Hengster
Paul
P
Rosenkranz
Alexander R
AR
Krugmann
Jens
J
Margreiter
Raimund
R
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D010951:Plasma Exchange; D020123:Sirolimus / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D020123:Sirolimus; D016559:Tacrolimus